Elicia Penuel

5.2k total citations · 3 hit papers
64 papers, 3.0k citations indexed

About

Elicia Penuel is a scholar working on Oncology, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Elicia Penuel has authored 64 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 34 papers in Pathology and Forensic Medicine and 28 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Elicia Penuel's work include Lymphoma Diagnosis and Treatment (31 papers), Monoclonal and Polyclonal Antibodies Research (26 papers) and CAR-T cell therapy research (23 papers). Elicia Penuel is often cited by papers focused on Lymphoma Diagnosis and Treatment (31 papers), Monoclonal and Polyclonal Antibodies Research (26 papers) and CAR-T cell therapy research (23 papers). Elicia Penuel collaborates with scholars based in United States, Canada and Australia. Elicia Penuel's co-authors include Greg S. Martin, Hartmut Koeppen, Yulei Wang, Matthew J. Matasar, Mark Merchant, Sarit Assouline, Luciana Burton, Emily Chan, Jane Fridlyand and Eva Lin and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Elicia Penuel

60 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

2012 884 citations Elicia Penuel, Luciana Burton et al. profile →
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

2019 459 citations Laurie H. Sehn, Alex F. Herrera et al. profile →
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

2022 244 citations Lihua E. Budde, Laurie H. Sehn et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elicia Penuel United States	22	2.0k	1.1k	975	698	385	64	3.0k
Drew Rasco United States	33	2.4k 1.2×	1.7k 1.5×	422 0.4×	296 0.4×	234 0.6×	192	4.1k
Muralidhar Beeram United States	27	1.7k 0.9×	1.3k 1.2×	243 0.2×	616 0.9×	182 0.5×	89	3.0k
Claudia Voena Italy	29	1.2k 0.6×	1.4k 1.2×	768 0.8×	187 0.3×	427 1.1×	57	3.2k
Morten Mau‐Sørensen Denmark	28	1.2k 0.6×	1.1k 1.0×	310 0.3×	187 0.3×	570 1.5×	130	2.7k
Shmuel Yaccoby United States	38	3.0k 1.5×	3.0k 2.7×	297 0.3×	391 0.6×	522 1.4×	112	5.5k
Catherine C. Park United States	22	1.3k 0.6×	946 0.8×	441 0.5×	350 0.5×	160 0.4×	37	2.9k
Minal Barve United States	25	1.8k 0.9×	1.3k 1.1×	290 0.3×	224 0.3×	97 0.3×	179	2.9k
Evelyne Lopez‐Crapez France	26	1.3k 0.6×	927 0.8×	524 0.5×	345 0.5×	84 0.2×	68	2.4k
Jennifer R. Diamond United States	26	2.0k 1.0×	998 0.9×	174 0.2×	400 0.6×	130 0.3×	136	3.0k
Marie Prewett United States	18	1.7k 0.8×	1.4k 1.3×	175 0.2×	661 0.9×	148 0.4×	34	2.9k

Countries citing papers authored by Elicia Penuel

Since Specialization

Citations

This map shows the geographic impact of Elicia Penuel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elicia Penuel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elicia Penuel more than expected).

Fields of papers citing papers by Elicia Penuel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elicia Penuel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elicia Penuel. The network helps show where Elicia Penuel may publish in the future.

Co-authorship network of co-authors of Elicia Penuel

This figure shows the co-authorship network connecting the top 25 collaborators of Elicia Penuel. A scholar is included among the top collaborators of Elicia Penuel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elicia Penuel. Elicia Penuel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Chi‐Chung, Chi‐Chung Li, Brendan C. Bender, et al.. (2024). A Novel Step‐Up Dosage Regimen for Enhancing the Benefit‐to‐Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma. Clinical Pharmacology & Therapeutics. 117(2). 465–474. 3 indexed citations

Budde, Lihua E., Matthew J. Matasar, Laurie H. Sehn, et al.. (2024). Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma. Blood. 144(Supplement 1). 1646–1646. 4 indexed citations

Schuster, Stephen J., Laurie H. Sehn, Nancy L. Bartlett, et al.. (2024). IBCL-335 Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After ≥2 Prior Therapies: 3-Year Follow-Up From a Pivotal Phase II Study. Clinical Lymphoma Myeloma & Leukemia. 24. S497–S497.

Bartlett, Nancy L., Laurie H. Sehn, Sarit Assouline, et al.. (2024). Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II. Blood. 144(Supplement 1). 1645–1645. 4 indexed citations

Besla, Rickvinder, Elicia Penuel, Ely Cosino, et al.. (2023). T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing. Cancer Immunology Research. 12(1). 60–71. 6 indexed citations

Maximov, Victor, Christopher R. Bolen, Andrew G. Polson, Elicia Penuel, & Elisabeth A. Lasater. (2023). Novel CD20 Mutations As a Mechanism of Resistance to CD20-CD3 Targeted Therapies in Non-Hodgkin's Lymphoma. Blood. 142(Supplement 1). 2808–2808. 1 indexed citations

Schuster, Stephen J., Ling‐Yuh Huw, Christopher R. Bolen, et al.. (2023). Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas. Blood. 143(9). 822–832. 34 indexed citations

Herrera, Alex F., Manish R. Patel, John M. Burke, et al.. (2022). Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study. Clinical Cancer Research. 28(7). 1294–1301. 21 indexed citations

Palomba, M. Lia, Brian G. Till, Steven I. Park, et al.. (2021). Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B‐Cell Lymphoma: Results from a Phase 1b Study. Clinical Lymphoma Myeloma & Leukemia. 22(7). e443–e451. 13 indexed citations

10.

Matasar, Matthew J., Chan Y. Cheah, Dok Hyun Yoon, et al.. (2020). Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts. Blood. 136(Supplement 1). 45–46. 27 indexed citations

11.

Piskol, Robert, Ling Huw, Ismail Sergin, et al.. (2019). A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer. Clinical Cancer Research. 25(14). 4431–4442. 40 indexed citations

12.

Tilly, Hervé, Franck Morschhauser, Nancy L. Bartlett, et al.. (2019). Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study. The Lancet Oncology. 20(7). 998–1010. 93 indexed citations

13.

Sehn, Laurie H., Alex F. Herrera, Matthew J. Matasar, et al.. (2017). Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study. Blood. 130. 2821–2821. 16 indexed citations

14.

Fayette, Jérôme, Lori J. Wirth, Cristina Oprean, et al.. (2016). Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). Frontiers in Oncology. 6. 232–232. 84 indexed citations

15.

Du, Xiangnan, Benjamin C. Lin, Ellen Ingalla, et al.. (2014). MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer. Clinical Cancer Research. 20(24). 6324–6335. 20 indexed citations

16.

Penuel, Elicia, Congfen Li, Luciana Burton, et al.. (2013). HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics. 12(6). 1122–1130. 20 indexed citations

17.

Trudel, Suzanne, P. Leif Bergsagel, Seema Singhal, et al.. (2012). A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma. Blood. 120(21). 4029–4029. 14 indexed citations

18.

Ghosh, Ritwik, Archana Narasanna, Shizhen Emily Wang, et al.. (2011). Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers. Cancer Research. 71(5). 1871–1882. 171 indexed citations

19.

Jain, Anjali, Elicia Penuel, Sheldon Mink, et al.. (2010). HER Kinase Axis Receptor Dimer Partner Switching Occurs in Response to EGFR Tyrosine Kinase Inhibition despite Failure to Block Cellular Proliferation. Cancer Research. 70(5). 1989–1999. 56 indexed citations

20.

Penuel, Elicia, Robert W. Akita, & Mark X. Sliwkowski. (2002). Identification of a Region within the ErbB2/HER2 Intracellular Domain That Is Necessary for Ligand-independent Association. Journal of Biological Chemistry. 277(32). 28468–28473. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact